<DOC>
	<DOCNO>NCT00003362</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide find melanoma cell may make body build immune response kill melanoma cell . Combining vaccine therapy immune adjuvant , GM-CSF , Montanide ISA-51 , QS21 , may effective treatment advance melanoma . PURPOSE : Randomized phase II trial study effectiveness gp 100-tyrosinase peptide vaccine one immune adjuvants GM-CSF , Montanide ISA-51 , QS21 treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Plus Immune Adjuvants Treating Patients With Advanced Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate immunogenicity gp100-tyrosinase peptide vaccine sargramostim ( GM-CSF ) , Montanide ISA-51 , QS21 adjuvant patient advance melanoma . II . Determine toxicity multiepitope melanoma peptide vaccine conjunction 3 adjuvant patient . III . Evaluate antitumor effect multiepitope melanoma peptide vaccine patient . OUTLINE : This randomize study . Patients stratify accord age ( 65 year vs 65 year ) previous systemic chemotherapy ( yes v ) . Patients randomize 1 3 treatment arm : Arm I ( Sargramostim ( GM-CSF ) adjuvant ) : Patients receive 3 monthly vaccination gp100-tyrosinase peptide vaccine administer intradermally week 1 , 5 , 9 . For vaccination , GM-CSF administer intradermally day 1-10 ; vaccine administer day 7 . Arm II ( Montanide ISA-51 ) : Patients receive 3 monthly vaccination gp100-tyrosinase peptide vaccine mixed Montanide ISA-51 administer subcutaneously ( SQ ) week 1 , 5 , 9 . Arm III ( QS21 adjuvant ) : Patients receive 3 monthly vaccination gp100-tyrosinase peptide vaccine mixed QS21 administer SQ week 1 , 5 , 9 . Patients stable respond disease may receive 3 additional monthly immunization begin 3-6 month follow completion 1 course immunization evidence T cell response either wild type peptide . Patients follow week 13 17 . PROJECTED ACCRUAL : A total 27 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable stage III stage IV melanoma Patients disease free follow surgical resection chemotherapy stage III IV disease also eligible HLAA201 positive PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 5 month Hematopoietic : WBC least 3,500/mm3 Platelet count least 75,000/mm3 LDH great 2 time upper limit normal No active bleeding Hepatic : Albumin least 3.5 mg/dL Renal : Not specify Other : Not pregnant less 3 month postpartum Fertile patient must use effective contraception No serious underlie medical condition No know immunodeficiency No active infection No retinal choroidal eye disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover No prior tyrosinase gp100 peptides No prior Montanide ISA51 No prior melanoma protein vaccine melanoma whole cell vaccines No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : At least 2 week since prior systemic steroid recover No concurrent systemic steroid Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiotherapy spleen No concurrent radiotherapy Surgery : Recovered prior surgery No prior splenectomy Other : At least 1 week since prior antiinflammatory drug recover At least 1 week since prior antihistamine recover No concurrent antiinflammatory drug No concurrent antihistamines No concurrent antimicrobial drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>